Clinical trials: Chronic Leukaemia
Chronic Lymphocytic Leukemia, CLL
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study).
- Trial name
- EPIC (NCT05557695)
- Testing
- Acalabrutinib
- Where
- 29 sites in United Kingdom
- Volunteers
- 287 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06637501
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 32 sites in United States, Brazil and 4 more
- Volunteers
- 94 people
- Sponsor
- BeOne Medicines
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Study to Evaluate the Safety and Tolerability of EP0042
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04581512
- Testing
- EP0042, Venetoclax, Azacitidine (AZA)
- Where
- 6 sites in Australia, Netherlands and 1 more
- Volunteers
- 70 people
- Sponsor
- Ellipses Pharma
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT00710528
- Testing
- CAL-101
- Where
- 9 sites in United States
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as…
- Conditions
- Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes
- Trial name
- NCT04891757
- Testing
- FHD-286, Low Dose Cytarabine, Decitabine
- Where
- 5 sites in United States
- Volunteers
- 144 people
- Sponsor
- Foghorn Therapeutics Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
- Trial name
- SEQUOIA (NCT03336333)
- Testing
- Zanubrutinib, Bendamustine, Rituximab
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 590 people
- Sponsor
- BeiGene
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are…
- Trial name
- NCT00123487
- Testing
- dasatinib
- Where
- 119 sites in United States, Argentina and 30 more
- Volunteers
- 638 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia
Asciminib RMP Study
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
- Trial name
- NCT05943522
- Testing
- Asciminib
- Where
- 17 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Novartis Pharmaceuticals
Indolent Non Hodgkin's Lymphoma (iNHL), Chronic Lymphocytic Leukaemia (CLL)
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region.
- Trial name
- NADIR (NCT02273856)
- Where
- 8 sites in Jordan, Kuwait and 5 more
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma International B.V.
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
- Trial name
- NCT04502030
- Testing
- Panzyga
- Where
- 84 sites in United States, Czechia and 10 more
- Volunteers
- 247 people
- Sponsor
- Octapharma
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Expanded Access Program of Ponatinib
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available…
- Trial name
- NCT01592136
- Testing
- ponatinib
- Where
- 33 sites in United States
- Sponsor
- Ariad Pharmaceuticals
Chronic Myeloid Leukemia
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib.
- Trial name
- NCT04048564
- Where
- 40 sites in France
- Volunteers
- 120 people
- Sponsor
- Incyte BioSciences France
CML, CML-CP,MMR,TKI
The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML
A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia. Randomized,Open Label,Control
- Trial name
- NCT02204644
- Testing
- Flumatinib 600mg qd, Imatinib 400mg qd
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01659021
- Testing
- Idelalisib, Ofatumumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 261 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia
A Phase I/II Study of GX15-070MS in Untreated CLL
This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.
- Trial name
- NCT00600964
- Testing
- GX15-070MS
- Where
- 5 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Gemin X
B-cell Chronic Lymphocytic Leukemia
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.
- Trial name
- CLL004 (NCT01982175)
- Testing
- Alemtuzumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in…
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
- Trial name
- CML (NCT05304377)
- Testing
- ELVN-001
- Where
- 45 sites in United States, Australia and 12 more
- Volunteers
- 250 people
- Sponsor
- Enliven Therapeutics
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer
- Trial name
- NCT02440685
- Testing
- ASN002 Dose Escalation, ASN002 RD
- Where
- 14 sites in United States, Argentina
- Volunteers
- 51 people
- Sponsor
- Asana BioSciences